Adimab LLC, Lebanon, New Hampshire 03766, USA.
Department of Immunology and Microbiology, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California 92037, USA.
Nat Rev Immunol. 2018 May;18(5):297-308. doi: 10.1038/nri.2017.148. Epub 2018 Jan 30.
Antibodies have been used for more than 100 years in the therapy of infectious diseases, but a new generation of highly potent and/or broadly cross-reactive human monoclonal antibodies (sometimes referred to as 'super-antibodies') offers new opportunities for intervention. The isolation of these antibodies, most of which are rarely induced in human infections, has primarily been achieved by large-scale screening for suitable donors and new single B cell approaches to human monoclonal antibody generation. Engineering the antibodies to improve half-life and effector functions has further augmented their in vivo activity in some cases. Super-antibodies offer promise for the prophylaxis and therapy of infections with a range of viruses, including those that are highly antigenically variable and those that are newly emerging or that have pandemic potential. The next few years will be decisive in the realization of the promise of super-antibodies.
抗体在传染病的治疗中已经使用了 100 多年，但新一代高效和/或广泛交叉反应的人源单克隆抗体（有时称为“超级抗体”）为干预提供了新的机会。这些抗体的分离主要是通过大规模筛选合适的供体和新的人类单 B 细胞单克隆抗体生成方法来实现的，其中大多数在人类感染中很少诱导产生。通过对抗体进行工程改造以提高半衰期和效应功能，在某些情况下进一步增强了它们的体内活性。超级抗体有望预防和治疗一系列病毒感染，包括那些具有高度抗原变异性的病毒，以及那些新出现或具有大流行潜力的病毒。未来几年将是超级抗体实现其承诺的决定性时期。
